Boehringer Ingelheim GmbH has signed a collaboration and licensing agreement with the Vienna-based F-Star Biotechnologische Forschungs-und Entwicklungsges to jointly discover new antibody-derived therapies. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
